Simultaneous Determination of Moxifloxacin and Flavoxate by RP-HPLC and Ecofriendly Derivative Spectrophotometry Methods in Formulations.

Mahesh Attimarad,Abdulmalek Ahmed Balgoname,Muhammad Shahzad Chohan

doi:10.3390/ijerph16071196

Abstract

Simple, fast, and precise reversed-phase (RP)-high-performance liquid chromatography (HPLC) and two ecofriendly spectrophotometric methods were established and validated for the simultaneous determination of moxifloxacin HCl (MOX) and flavoxate HCl (FLX) in formulations. Chromatographic methods involve the separation of two analytes using an Agilent Zorbax SB C18 HPLC column (150 mm × 4.6 mm; 5 µm) and a mobile phase consisting of phosphate buffer (50 mM; pH 5): methanol: acetonitrile in a proportion of 50:20:30 v/v, respectively. Valsartan was used as an internal standard. Analytes were monitored by measuring the absorbance of elute at 299 nm for MOX and 250 nm for FLX and valsartan. Two environmentally friendly spectrophotometric (first derivative and ratio first derivative) methods were also developed using water as a solvent. For the derivative spectrophotometric determination of MOX and FLX, a zero-crossing technique was adopted. The wavelengths selected for MOX and FLX were −304.0 nm and −331.8 nm for the first derivative spectrophotometric method and 358.4 nm and −334.1 nm for the ratio first-derivative spectrophotometric method, respectively. All methods were successfully validated, as per the International Conference on Harmonization(ICH) guidelines, and all parameters were well within acceptable ranges. The proposed analytical methods were successfully utilized for the simultaneous estimation of MOX and FLX in formulations.

Highlights

Moxifloxacin hydrochloride (MOX; Figure 1A) is a broad-spectrum fluoroquinolone antibacterial agent used in the treatment of eye, respiratory tract, lung, and urinarytract infections, and it is used to treat skin allergies, pneumonia, and abdominal bacterial infections
All important high-performance liquid chromatography (HPLC) conditions that induced the chromatographic separation of MOX and Flavoxate hydrochloride (FLX), along with the internal standard, were optimized to obtain high-resolution spectra with good peak shape and accurate quantitative estimation of MOX and FLX
To obtain good chromatographic separation and high-resolution spectra for MOX and FLX, along with the internal standard, different RP-HPLC columns and different proportions of the most common HPLC solvents, methanol, acetonitrile, water, or buffer as a mobile phase were tried. Good separation of both drugs along with the internal standard was achieved by isocratic elution using an Agilent Zorbax SB C18 HPLC column (150 mm × 4.6 mm; 5 μm internal diameter)

Summary

Introduction

Moxifloxacin hydrochloride (MOX; Figure 1A) is a broad-spectrum fluoroquinolone antibacterial agent used in the treatment of eye, respiratory tract, lung, and urinarytract infections, and it is used to treat skin allergies, pneumonia, and abdominal bacterial infections. Flavoxate hydrochloride (FLX; Figure 1B) is a flavone derivative that acts as a strong smooth-muscle relaxant. Different mechanisms of action are reported for FLX, as it acts as a calcium antagonist, phosphodiesterase enzyme inhibitor, and local anesthetic.

Methods

Results

Conclusion